title: [A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
abstract: A 61-year-old woman was visited our hospital for a left breast tumor. Ultrasonography (US) demonstrated two tumors comprising a tumor 3.3 cm in diameter in the A area and another one 0.9 cm in diameter in the C area of the left breast, and US-guided core needle biopsy (CNB) was performed. The histological findings showed invasive ductal carcinoma, ER (+)/PR (-)/HER2 (+) in the A lesion and ER (+)/PR (+)/HER2 (-) in the C lesion. At this point in time, US demonstrated a new tumor 1.9 cm in diameter in the outside C area of the left breast, and CNB was performed. The histological findings showed invasive ductal carcinoma, ER (+)/PR (+)/HER2 (-) in the outside C lesion. Chemotherapy was estimated as PD, and an operation was performed (Bt + Ax). Histopathological examination showed pCR in the A lesion, invasive lobular carcinoma in the C lesion and solid-tubular carcinoma in the outside C new lesion. Depend on each subtype, HER2/new targeting trastuzumab therapy, radiation therapy and ER/PR targeting hormone therapy were tried as a post operative treatment.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: Hidemi
authors.initials: H
authors.lastname: Kawajiri
authors.forename: Satoru
authors.initials: S
authors.lastname: Noda
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takashima
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Onoda
authors.forename: Bunzo
authors.initials: B
authors.lastname: Nakata
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kato
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000473:pathology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil